Novel Aspects of Bone Biology
Organizer(s): Gerard Karsenty and David T. ScaddenDate: June 13 - 16, 2018
Location: Snowbird Resort, Snowbird, UT, USA
This conference presents recent progress made in two relatively novel areas of skeletal biology not covered by other meetings. The first one is the cross-talk between bone, hematopoiesis and leukemogenesis. The second is the study of the various endocrine functions of bone and how their study impacts on our understanding of multiple degenerative diseases. Meetings of bone biology are traditionally dominated by the need to explain the basis and to propose treatments for the most frequent bone disease: osteoporosis. Aside from this very vivid field, these two other novel aspects of bone biology have developed in the last decade. A shared feature is that they link bone biology to multiple other organs and to other functions besides making bones. This conference showcases the many advances made in these two aspects of skeleton biology and how these developments have enriched our understanding of the pathogenesis of multiple degenerative diseases affecting the bone marrow, energy metabolism or the brain. Because of its very nature, this conference brings together investigators from different fields rarely afforded an opportunity to meet.
Scholarship Deadline: February 27 2018
Discounted Abstract Deadline: February 27 2018
Abstract Deadline: March 27 2018
Discounted Registration Deadline: April 12 2018
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Grant No. 1R13AR073678-01
Funding for this conference was made possible (in part) by 1R13AR073678-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.